An epidemiological model for prediction of endometrial cancer risk in Europe

European Journal of Epidemiology

Volumn 31, Issue 1, 2016, Pages 51-60

  Hüsing, Anika ^a   Dossus, Laure ^b,c,d   Ferrari, Pietro ^e   Tjønneland, Anne ^f   Hansen, Louise ^f   Fagherazzi, Guy ^b,c,d   Baglietto, Laura ^g,h   Schock, Helena ^a   Chang Claude, Jenny ^a   Boeing, Heiner ⁱ   Steffen, Annika ⁱ   Trichopoulou, Antonia ^j,k   Bamia, Christina ^l   Katsoulis, Michalis ^j   Krogh, Vittorio ^m   Palli, Domenico ⁿ   Panico, Salvatore ^o   Onland Moret, N Charlotte ^p,q   Peeters, Petra H ^p,q   Bueno de Mesquita, H Bas ^p,q,r   Weiderpass, Elisabete ^s,t,u,v   Gram, Inger T ^s   Ardanaz, Eva ^w,x   Obón Santacana, Mireia ^y   Navarro, Carmen ^x,z,aa   Sánchez Cantalejo, Emilio ^x,ab   Etxezarreta, Nerea ^x,ac   Allen, Naomi E ^ad   Khaw, Kay Tee ^ae   Wareham, Nick ^af   Rinaldi, Sabina ^e   Romieu, Isabelle ^e   Merritt, Melissa A ^q   Gunter, Marc ^q   Riboli, Elio ^q   Kaaks, Rudolf ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d IGR   (France)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^g CANCER EPIDEMIOLOGY CENTRE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^j HELLENIC HEALTH FOUNDATION   (Greece)

^k BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^l UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^o UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^p UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^q IMPERIAL COLLEGE LONDON   (United Kingdom)

^r NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^s UNIVERSITY OF TROMSØ   (Norway)

^t CANCER REGISTRY OF NORWAY   (Norway)

^u KAROLINSKA INSTITUTE   (Sweden)

^v FOLKHÄLSAN RESEARCH CENTER   (Finland)

^w INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^x CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^y CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^z DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^aa UNIVERSITY OF MURCIA   (Spain)

^ab ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^ac BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^ad UNIVERSITY OF OXFORD   (United Kingdom)

^ae UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^af UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

Endometrial cancer; Epidemiology; Prevention; Risk model

Indexed keywords

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CAUSAL MODELING; ENDOMETRIUM CANCER; EUROPE; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; ORAL CONTRACEPTIVE USE; PREDICTION; RISK FACTOR; SMOKING; BIOLOGICAL MODEL; BODY MASS; ENDOMETRIAL NEOPLASMS; INCIDENCE; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; BODY MASS INDEX; ENDOMETRIAL NEOPLASMS; EUROPE; FEMALE; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84958752384     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-015-0030-9     Document Type: Article

References (32)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403. doi:10.1016/j.ejca.2012.12.027.
2. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78. doi:10.1016/S0140-6736(08)60269-X.
3. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365(9470):1543–51. doi:10.1016/S0140-6736(05)66455-0.
4. Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol. 2010;172(12):1394–403. doi:10.1093/aje/kwq300.
5. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;127(2):442–51. doi:10.1002/ijc.25050.
6. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27(5):1327–31. doi:10.1093/humrep/des042.
7. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomark Prev. 2002;11(12):1531–43.
8. Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab. 2011;96(2):255–64. doi:10.1210/jc.2010-0536.
9. Lacey JV Jr, Chia VM, Rush BB, et al. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan. Int J Cancer. 2012;131(8):1921–9. doi:10.1002/ijc.27457.
10. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011;22(4):145–52. doi:10.1016/j.tem.2011.01.005.
11. Gail MH. Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med. 2011;30(10):1090–104. doi:10.1002/sim.4187.
12. Jacobs I, Gentry-Maharaj A, Burnell M, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 2011;12(1):38–48. doi:10.1016/S1470-2045(10)70268-0.
13. Friedenreich C, Cust A, Lahmann PH, et al. Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Cancer Causes Control. 2007;18(4):399–413. doi:10.1007/s10552-006-0113-8.
14. Friedenreich C, Cust A, Lahmann PH, et al. Physical activity and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Int J Cancer. 2007;121(2):347–55. doi:10.1002/ijc.22676.
15. Al-Zoughool M, Dossus L, Kaaks R, et al. Risk of endometrial cancer in relationship to cigarette smoking: results from the EPIC study. Int J Cancer. 2007;121(12):2741–7. doi:10.1002/ijc.22990.
16. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):1113–24.
17. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389–430. doi:10.1002/sim.2712.
18. Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109–23. doi:10.1002/sim.1802.
19. Pencina M, D’Agostino R, D’Agostino R, Vasan R. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72.
20. Hosmer David W, Stanley Lemeshow P. Applied logistic regression. 2nd ed. New York: Wiley; 2000.
21. Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: IARC CancerBase No. 10. http://globocan.iarc.fr/. 2008.
22. Anothaisintawee T, Teerawattananon Y, Wiratkapun C, Kasamesup V, Thakkinstian A. Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat. 2012;133(1):1–10. doi:10.1007/s10549-011-1853-z.
23. Husing A, Canzian F, Beckmann L, et al. Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. J Med Genet. 2012;49(9):601–8. doi:10.1136/jmedgenet-2011-100716.
24. Pfeiffer RM, Park Y, Kreimer AR, et al. Risk Prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med. 2013;10(7):e1001492. doi:10.1371/journal.pmed.1001492.
25. Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16(6):631–50. doi:10.1093/humupd/dmq022.
26. Lu KH, Loose DS, Yates MS, et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila). 2013;6(8):774–81. doi:10.1158/1940-6207.CAPR-13-0020.
27. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009;4:CD007245. doi:10.1002/14651858.CD007245.pub2.
28. Breijer MC, Peeters JA, Opmeer BC, et al. Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2012;40(6):621–9. doi:10.1002/uog.12306.
29. Burbos N, Musonda P, Giarenis I, et al. Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool. Br J Cancer. 2010;102(8):1201–6. doi:10.1038/sj.bjc.6605620.
30. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2008;15(2):485–97. doi:10.1677/ERC-07-0064.
31. Dossus L, Lukanova A, Rinaldi S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort—a factor analysis. Am J Epidemiol. 2013;177(8):787–99.
32. Angioli R, Capriglione S, Aloisi A, et al. REM (risk of endometrial malignancy): a proposal for a new scoring system to evaluate risk of endometrial malignancy. Clin Cancer Res. 2013;19(20):5733–9.